Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:CGON NASDAQ:GMTX NASDAQ:MLYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$21.08+6.4%$22.69$12.21▼$39.50$554.62M-0.19737,132 shs510,080 shsCGONCG Oncology$38.82+2.9%$27.77$14.80▼$40.47$2.96B0.871.00 million shs1.25 million shsGMTXGemini Therapeutics$61.04+1.2%$59.44$1.16▼$14.10$2.64B-0.12189,291 shs418,250 shsMLYSMineralys Therapeutics$39.87+6.9%$19.81$8.24▼$40.33$2.64B-0.291.09 million shs1.53 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+2.11%-13.04%-1.05%-15.31%-47.17%CGONCG Oncology+5.48%+12.16%+44.36%+43.53%-0.08%GMTXGemini Therapeutics+0.73%0.00%+0.80%+20.46%+26.55%MLYSMineralys Therapeutics-0.35%-3.29%+143.09%+171.60%+211.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$21.08+6.4%$22.69$12.21▼$39.50$554.62M-0.19737,132 shs510,080 shsCGONCG Oncology$38.82+2.9%$27.77$14.80▼$40.47$2.96B0.871.00 million shs1.25 million shsGMTXGemini Therapeutics$61.04+1.2%$59.44$1.16▼$14.10$2.64B-0.12189,291 shs418,250 shsMLYSMineralys Therapeutics$39.87+6.9%$19.81$8.24▼$40.33$2.64B-0.291.09 million shs1.53 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+2.11%-13.04%-1.05%-15.31%-47.17%CGONCG Oncology+5.48%+12.16%+44.36%+43.53%-0.08%GMTXGemini Therapeutics+0.73%0.00%+0.80%+20.46%+26.55%MLYSMineralys Therapeutics-0.35%-3.29%+143.09%+171.60%+211.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$46.13118.81% UpsideCGONCG Oncology 2.92Moderate Buy$56.0044.26% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AMLYSMineralys Therapeutics 2.83Moderate Buy$43.509.10% UpsideCurrent Analyst Ratings BreakdownLatest ANAB, GMTX, CGON, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/17/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$56.00 ➝ $79.009/16/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$45.009/15/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.009/11/2025MLYSMineralys TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$26.00 ➝ $50.009/9/2025MLYSMineralys TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $52.009/8/2025CGONCG OncologyJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.009/8/2025CGONCG OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$75.009/8/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.009/5/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.009/3/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$15.00 ➝ $26.009/1/2025CGONCG OncologyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$123.16M4.79N/AN/A$2.33 per share9.05CGONCG Oncology$1.14M2,596.51N/AN/A$9.63 per share4.03GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AMLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)CGONCG Oncology-$88.04M-$1.77N/AN/AN/A-15,945.17%-19.37%-18.72%11/11/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AMLYSMineralys Therapeutics-$177.81M-$3.56N/AN/AN/AN/A-70.44%-65.51%11/10/2025 (Estimated)Latest ANAB, GMTX, CGON, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MLYSMineralys Therapeutics-$0.78-$0.66+$0.12-$0.66N/AN/A8/8/2025Q2 2025CGONCG Oncology-$0.49-$0.54-$0.05-$0.54$0.11 millionN/A8/6/2025Q2 2025ANABAnaptysBio-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.228.22CGONCG OncologyN/A22.1522.15GMTXGemini TherapeuticsN/A71.4971.49MLYSMineralys TherapeuticsN/A15.1215.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ACGONCG Oncology26.56%GMTXGemini Therapeutics75.42%MLYSMineralys Therapeutics84.46%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%CGONCG Oncology7.40%GMTXGemini Therapeutics12.90%MLYSMineralys Therapeutics25.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10028.00 million18.62 millionOptionableCGONCG Oncology6176.25 million70.61 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableMLYSMineralys Therapeutics2866.29 million49.35 millionOptionableANAB, GMTX, CGON, and MLYS HeadlinesRecent News About These CompaniesMineralys Therapeutics (NASDAQ:MLYS) Insider Sells $409,212.00 in StockSeptember 17 at 8:23 PM | marketbeat.comDid New Phase 3 Results and FDA Milestones Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?September 17 at 4:53 PM | finance.yahoo.comSwedbank AB Takes $5.20 Million Position in Mineralys Therapeutics, Inc. $MLYSSeptember 17 at 3:45 AM | marketbeat.comGoldman Sachs Group Inc. Purchases 186,480 Shares of Mineralys Therapeutics, Inc. $MLYSSeptember 17 at 3:35 AM | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Trading Down 5% - Should You Sell?September 16 at 4:32 PM | marketbeat.comMineralys Therapeutics falls -4.9%September 15 at 7:18 PM | msn.comMineralys Therapeutics (NASDAQ:MLYS) Sees Unusually-High Trading Volume Following Analyst UpgradeSeptember 13, 2025 | marketbeat.comWells Fargo & Company Increases Mineralys Therapeutics (NASDAQ:MLYS) Price Target to $50.00September 13, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume on Analyst UpgradeSeptember 13, 2025 | americanbankingnews.comMineralys Therapeutics (NASDAQ:MLYS) Price Target Raised to $50.00 at Wells Fargo & CompanySeptember 12, 2025 | americanbankingnews.comMineralys Therapeutics price target raised to $50 from $26 at Wells FargoSeptember 11, 2025 | msn.comThe Goldman Sachs Group Increases Mineralys Therapeutics (NASDAQ:MLYS) Price Target to $52.00September 11, 2025 | marketbeat.comJefferies Reaffirms Their Hold Rating on Mineralys Therapeutics, Inc. (MLYS)September 10, 2025 | theglobeandmail.comMineralys Therapeutics (NASDAQ:MLYS) Director Srinivas Akkaraju Acquires 588,235 Shares of StockSeptember 10, 2025 | marketbeat.comRa Capital Management, L.P. Acquires 1,176,470 Shares of Mineralys Therapeutics (NASDAQ:MLYS) StockSeptember 10, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Reaches New 52-Week High - Here's WhySeptember 10, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Mineralys Therapeutics (NASDAQ:MLYS)September 10, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Given New $52.00 Price Target at The Goldman Sachs GroupSeptember 10, 2025 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Mineralys Therapeutics (NASDAQ:MLYS)September 10, 2025 | americanbankingnews.comWhat Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?September 9, 2025 | zacks.comPolar Asset Management Partners Inc. Sells 78,970 Shares of Mineralys Therapeutics, Inc. $MLYSSeptember 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANAB, GMTX, CGON, and MLYS Company DescriptionsAnaptysBio NASDAQ:ANAB$21.08 +1.27 (+6.41%) Closing price 04:00 PM EasternExtended Trading$20.58 -0.50 (-2.40%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.CG Oncology NASDAQ:CGON$38.82 +1.10 (+2.92%) Closing price 04:00 PM EasternExtended Trading$39.01 +0.19 (+0.49%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Gemini Therapeutics NASDAQ:GMTX$61.04 +0.70 (+1.15%) As of 09/17/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Mineralys Therapeutics NASDAQ:MLYS$39.87 +2.58 (+6.92%) Closing price 04:00 PM EasternExtended Trading$41.00 +1.13 (+2.83%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
